Improved DNA-based tests to find early esophagus and colon cancer risk
Biomarker Developmental Unit
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11167434
This project builds and tests DNA and epigenetic lab tests to help find people with Barrett's esophagus or colon polyps who are more likely to develop cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11167434 on ClinicalTrials.gov |
What this research studies
Researchers will analyze tissue samples from people with Barrett's esophagus and from the colon to look for DNA methylation and genetic changes linked to cancer risk. They will create clinical-grade (GLP-compliant) lab assays that aim to detect high-grade changes and early cancer and to predict which Barrett or polyp patients are likely to progress. The team will validate these assays using patient samples and clinical follow-up data to see how well the tests identify people who need closer surveillance. If accurate, the tests could be used alongside routine care to guide how often someone gets a follow-up scope.
Who could benefit from this research
Good fit: People with Barrett's esophagus and people with a history of colon adenomas or other elevated colorectal cancer risk are the most likely candidates for these tests.
Not a fit: People without Barrett's esophagus, without colorectal polyps, or those who already have advanced cancer are unlikely to benefit from these early-detection assays.
Why it matters
Potential benefit: If successful, these tests could catch early cancers or identify people who need more frequent monitoring, potentially preventing deaths from esophageal and colorectal cancer.
How similar studies have performed: DNA methylation tests have shown promise for colorectal cancer screening, but using methylation and genetic assays specifically to predict Barrett's progression and early esophageal cancer is newer and less proven.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YEUNG, CECILIA C — FRED HUTCHINSON CANCER CENTER
- Study coordinator: YEUNG, CECILIA C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Barrett Syndrome